Tag: GlobeNewswire

MINNEAPOLIS, Oct. 01, 2026 (GLOBE NEWSWIRE) — Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that the American Medical Association (AMA) CPT^® Editorial Panel has approved the establishment of a new set of Current Procedural Terminology (CPT^®) codes that accurately describe and include the Inspire V system. The new Category I codes are scheduled to take effect on January 1, 2028.

“This new CPT code language addresses the implantation of a single lead and an implantable pulse generator (IPG) including our recently launched Inspire V system,” said Tim Herbert, Chairman and Chief Executive Officer of Inspire Medical Systems. “We appreciate the AMA creating dedicated codes that will create a clearer, more consistent path for coding and reimbursement, which we expect will reduce administrative burden for hospitals and physicians and support continued growth in patient access to Inspire therapy. The application received broad society support with special thanks to the American Academy of Otolaryngology-Head and the Neck Surgery (AAO-HNS), the American Academy of Sleep Medicine (AASM) and the International Surgical Sleep Society (ISSS) for their support addressing the need to act now to provide a permanent coding solution for the Inspire V system and other single lead hypoglossal nerve stimulation IPG therapies.”

With the new codes created, the Centers for Medicare & Medicaid Services (CMS) will conduct its standard process to determine the value for each new CPT code, which determines the payments for that service under Medicare. CMS typically requests the AMA Relative Value Scale Update Committee (RUC) to review specific codes and evaluate whether physician time, work and expenses for related services have changed over time.

Specialty societies, such as the AAO-HNS, may survey their members and make recommendations to the RUC based on the output from the rigorous methodology for these surveys. These surveys would collect information regarding physician work including both time and complexity, practice expenses including clinical staff and any required supplies and equipment, and liability insurance. Sufficient physicians are surveyed to ensure accuracy of data collected.

After collecting and reviewing the data, the RUC recommendation is provided to CMS who we expect would publish their proposed valuation in July 2027 with final valuations published in November 2027.

The new Category I CPT codes reflect a growing body of clinical evidence supporting therapies like Inspire’s closed-loop implantable device, Inspire V, which is designed to work with a patient’s natural breathing to help keep the airway open during sleep. With more than 140,000 patients treated and over a decade of clinical experience, Inspire is a well-established leader in the treatment of OSA.

About Inspire Medical Systems

Inspire Medical Systems is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA, EU MDR, and PDMA-approved neurostimulation technology that provides safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements regarding the anticipated implementation and effective date of the newly approved CPT^® codes and the potential impact of such codes on coding, reimbursement, patient access, and adoption of Inspire therapy. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” and similar expressions.

These forward-looking statements are based on management’s current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information regarding these risks and uncertainties can be found under the caption “Risk Factors” in Inspire Medical Systems, Inc.’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.

Any forward-looking statements contained in this press release speak only as of the date hereof. Inspire undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Investor Contact

Brian Johnston or Louisa Smith

Gilmartin Group, LLC

IR@inspiresleep.com

NEW HAVEN, Conn., Oct. 01, 2026 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that novel biomarker data from a Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease will be presented as late-breaking oral and poster presentations at the 2026 International Congress of Parkinson’s Disease and Movement Disorders® (MDS), taking place October 4-8, 2026, in Seoul, Korea.

ARV-102 is Arvinas’ investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2 (LRRK2), a multifunctional protein that has been implicated in Parkinson’s disease and progressive supranuclear palsy (PSP).

The presentation details are as follows:

Presentation Title: Phase 1 Study of ARV-102, a PROTAC LRRK2 Degrader, in Parkinson’s Disease: Oculomotor and Biomarker Data
Session Number: 12
Session Title: Late-Breaking Abstracts: Parkinson’s Disease
Session Type: Oral
Session Location: Conference Room E3, 3rd Floor
Presentation Number: LBA 15
Presentation Order: 3
Presentation Duration: 5 minutes
Date: Wednesday, October 7
Session Time: 12:30 – 13:30 ET

Presentation Title: Phase 1 Study of ARV-102, a PROTAC LRRK2 Degrader, in Parkinson’s Disease: Oculomotor and Biomarker Data
Session Type: E-Poster
Session Location: E-Poster Hall, online
Presentation Number: LBA 15

Additional information including abstracts can be found on the 2026 MDS Congress website.

About ARV-102
ARV-102 is an investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) designed to cross the blood-brain barrier and specifically target and degrade leucine-rich repeat kinase (LRRK2), a large, multidomain scaffolding kinase with GTPase activity. Increased activity and over expression of LRRK2 have been implicated in the pathogenesis of neurological diseases, including LRRK2 genetic and idiopathic Parkinson’s disease and progressive supranuclear palsy (PSP). ARV-102 has been evaluated in a Phase 1 clinical trial in healthy volunteers and in patients with Parkinson’s disease.

About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROteolysis TArgeting Chimera (PROTAC) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas, with its partner Pfizer, developed the first U.S. Food and Drug Administration (FDA)-approved PROTAC, a type of heterobifunctional protein degrader, which has been outlicensed to Rigel Pharmaceuticals, Inc. for exclusive global development, manufacturing, and commercialization.

Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle for spinal-bulbar muscular atrophy, also known as Kennedy’s disease; and ARV-6723, targeting hematopoietic progenitor kinase 1 (HPK1) for advanced solid tumors. Arvinas has also advanced ARV-806, targeting Kirsten rat sarcoma (KRAS) G12D for solid tumors, in the clinic, and previously announced plans to seek an out-licensing agreement for any additional clinical trials of ARV-806, including dose expansion or combination clinical trials. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding: the potential of ARV-102, including its degradation of leucine-rich repeat kinase 2 (“LRRK2”), and its potential treatment of neurodegenerative diseases, including Parkinson’s disease and progressive supranuclear palsy (“PSP”); and Arvinas’ plans with respect to its clinical development programs. All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas’ strategy, development plans, future operations, prospects, plans, and objectives of management and the statements identified in the prior paragraph, are forward-looking statements. The words “ability,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “target,” “goal,” “aim,” “whether,” “will,” “would,” “could,” “reliance,” “should,” “look forward,” “seek,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Arvinas may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas will be able to successfully conduct and complete development for its product candidates, including ARV-102, on its current timelines or at all; risks related to clinical trial results and the interpretation thereof, including with respect to ARV-102; Arvinas’ ability to protect its intellectual property portfolio; Arvinas’ reliance on third parties; whether Arvinas will be able to raise capital when needed; whether Arvinas’ cash and cash equivalents will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the “Risk Factors” section of Arvinas’ Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent other reports filed with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas’ current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas’ views as of any date subsequent to the date of this release.

Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
jeff.boyle@arvinas.com

Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com

ReplimuneConnect Plus a comprehensive program that provides dedicated support and resources to help eligible patients access TUDRIQEV in the U.S. now live

WOBURN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that TUDRIQEV™ (vusolimogene oderparepvec-wtpg) is now commercially available in the United States. TUDRIQEV is indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.

This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).

TUDRIQEV received accelerated approval from the U.S. Food and Drug Administration in early August. Beginning today, healthcare providers can order TUDRIQEV for next day delivery.

“With TUDRIQEV now available, we have reached a critical milestone in bringing this therapy to patients with advanced melanoma who have been waiting for a new option,” said Sushil Patel, Ph.D., Chief Executive Officer of Replimune. “I’m deeply proud of our team, who moved with urgency to put the infrastructure and comprehensive patient support services in place so that healthcare providers can access this therapy with next day delivery when their patients need it.”

Administration
TUDRIQEV is administered by direct intratumor injection into superficial, deep, and/or visceral lesions, with imaging guidance used for deep or visceral lesions. It is given once every two weeks for eight consecutive doses, with the dose based on tumor size; a lower concentration is used for the first dose and a higher concentration for subsequent doses. Nivolumab is administered intravenously beginning at week three. Please see the full Prescribing Information for complete dosing, preparation, handling, and administration instructions.

Clinical Data Supporting Approval
The accelerated approval was based on the registrational anti-PD-1-failed melanoma cohort of the IGNYTE trial, which enrolled 140 patients. Among the 91 efficacy-evaluable patients with at least one non-injected lesion, TUDRIQEV plus nivolumab achieved an objective response rate of 24.2% (95% CI: 15.8, 34.3) with a median duration of response of 14.1 months (95% CI: 10.7, not reached).

A confirmatory Phase 3 trial, IGNYTE-3 (NCT06264180), is ongoing.

ReplimuneConnect Plus Patient Support Program
Replimune is committed to helping eligible patients in the U.S. access treatment with TUDRIQEV. ReplimuneConnect Plus is a comprehensive program that provides information and support on access, reimbursement, and financial assistance for eligible patients who are prescribed TUDRIQEV, including benefits investigation, co-pay assistance for eligible commercially insured patients, referrals to independent foundations, and case manager support.

Patients, caregivers, and healthcare providers can learn more and enroll at replimuneconnectplus.com or by calling 1-833-775-7587, Monday through Friday from 8 AM to 8 PM ET.

About Melanoma
Melanoma is the fifth most common cancer, with approximately 105,000 new cases estimated in the U.S. in 2025, and the most lethal form of skin cancer, accounting for nearly 8,500 deaths annually. Standard of care includes immune checkpoint blockade, to which approximately half of patients will not respond or will progress after treatment. For patients who progress following anti-PD-1 therapy, treatment options are limited.

About TUDRIQEV™ (vusolimogene oderparepvec-wtpg)
TUDRIQEV is a genetically modified herpes simplex virus type 1 (HSV-1) oncolytic viral therapy that encodes a fusogenic glycoprotein derived from gibbon ape leukemia virus with the R sequence deleted (GALV-GP-R–) and human granulocyte macrophage colony-stimulating factor (GM-CSF). The genes encoding the HSV-1 neurovirulence factor ICP34.5 and the ICP47 inhibitor of antigen presentation are deleted. TUDRIQEV preferentially replicates within tumors, leading to tumor lysis and release of tumor and viral antigens. In combination with nivolumab, TUDRIQEV may promote an anti-tumor immune response in the anti-PD-1-resistant setting. For more information, visit Tudriqev.com.

INDICATION
TUDRIQEV (vusolimogene oderparepvec-wtpg) is indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.
This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).

IMPORTANT SAFETY INFORMATION

Warnings and Precautions
Accidental Exposure to TUDRIQEV: Healthcare providers, caregivers, close contacts, pregnant women, newborns, and patients should avoid direct contact with injected tumors, dressings, or bodily fluids of patients. Should accidental exposure occur, clean the affected area.

Herpetic Infection or Reactivation: Assess and treat suspected herpetic lesions as clinically warranted.

Visceral Injury: Monitor patients for signs and symptoms of visceral injury during and after TUDRIQEV administration and manage accordingly.

Adverse Reactions
Serious adverse reactions occurred in 35% of 140 patients who received TUDRIQEV in combination with nivolumab, including 2 patients each with arthralgia, hypophysitis, immune-mediated enterocolitis, and pyrexia. Adverse reactions leading to permanent discontinuation of TUDRIQEV occurred in 2.9% of 140 patients and were 1 each of amylase increased, lipase increased, myocarditis, and pneumonitis.

The most common non-laboratory adverse reactions (incidence >10%) are fatigue, pyrexia, chills, musculoskeletal pain, nausea, diarrhea/colitis, injection site reaction, headache, cough, influenza-like illness, vomiting, pruritus, arthralgia, asthenia, constipation, decreased appetite, dizziness, skin/superficial infection, and dyspnea.

Drug Interactions
Antivirals: Delay TUDRIQEV administration for 72 hours.

Use in Specific Populations
Females and Males of Reproductive Potential: Advise females of reproductive potential, and males with a female partner of reproductive potential, to use effective contraception during TUDRIQEV treatment and for 90 days after the last dose.

Please report any adverse event or product quality complaint related to a Replimune product by calling 1-877-375-0095. You may also contact the FDA directly at www.fda.gov/medwatch or 1-800-FDA-1088.

Please see full Prescribing Information, including Patient Information, at www.replimune.com/medicines. Please also refer to the full Prescribing Information for nivolumab.

About Replimune
Replimune Group, Inc., headquartered in Woburn, Massachusetts, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. TUDRIQEV is the company’s first commercially available product. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and induce a systemic anti-tumor immune response. For more information, visit www.replimune.com and follow the company on LinkedIn and X.

Forward-Looking Statements
This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs, sufficiency of any resulting data), our ability to execute on our strategic or financial initiatives, and potential commercial viability, and potential reimbursement and utilization of TUDRIQEV involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Our ability to maintain TUDRIQEV’s accelerated approval and to continue commercialization of TUDRIQEV may be contingent on verification of clinical benefit in a confirmatory trial(s). Other forward looking statements may be identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited experience in commercializing products for sale, our ability to successfully verify the clinical benefit of TUDRIQEV in our ongoing confirmatory Phase 3 trial, IGNYTE-3, our ability to meet our product manufacturing goal, the timing and scope of future regulatory approvals, the availability of combination therapies needed to conduct our clinical trials, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, the impact of political and global macro factors and military conflicts, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.

Investor Inquiries
Chris Brinzey
ICR Healthcare
339.970.2843
chris.brinzey@icrhealthcare.com

Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com

Sixty-five consecutive quarters of quarterly common stock dividend increases

LITTLE ROCK, Ark., Oct. 01, 2026 (GLOBE NEWSWIRE) — Bank OZK (the “Bank”) (Nasdaq: OZK) announced its Board of Directors declared a quarterly cash dividend on the Bank’s common stock of $0.49 per share, up $0.01, or 2.08% from the prior quarter. The common stock dividend is payable on October 20, 2026 to shareholders of record as of October 13, 2026. This marks the Bank’s 65^th consecutive increase in its quarterly common stock dividend.

The Board of Directors also declared a quarterly cash dividend of $0.28906 per share on the Bank’s 4.625% Series A Non-Cumulative Perpetual Preferred Stock (“Series A Preferred Stock”) (Nasdaq: OZKAP) for the period covering August 15, 2026 through, but excluding November 15, 2026. The Series A Preferred Stock dividend is payable on November 16, 2026, to holders of record of the Series A Preferred Stock at the close of business on November 2, 2026.

Bank OZK’s consistent track record of increasing its common stock dividend has led to it being included in the S&P High Yield Dividend Aristocrats^® index (Ticker: SPHYDA) since January 2018. The index consists of members of the S&P Composite 1500^® that have followed a managed-dividends policy of consistently increasing common stock dividends every year for at least 20 years, and that meet minimum float-adjusted market capitalization and liquidity requirements. For more information on the index, visit www.spglobal.com/spdji.

GENERAL INFORMATION
Bank OZK (Nasdaq: OZK) is a regional bank providing innovative financial solutions delivered by expert bankers with a relentless pursuit of excellence. Established in 1903, Bank OZK conducts banking operations in 267 offices in nine states including Arkansas, Georgia, Florida, Texas, North Carolina, Tennessee, New York, California and Mississippi and had $41.7 billion in total assets as of June 30, 2026. For more information, visit ozk.com.

Investor Relations Contact:	Jay Staley (501) 906-7842
Media Contact:	Michelle Rossow (501) 906-3922

Acquisition extends Nayax’s payments leadership into mobility with a market-leading smart parking platform serving more than 250,000 parking spaces

HERZLIYA, Israel, Oct. 01, 2026 (GLOBE NEWSWIRE) — Nayax Ltd. (Nasdaq: NYAX; TASE: NYAX), a global commerce enablement, payments, and loyalty platform designed to help merchants scale their business, today announced it has completed its acquisition of IPS Group, Inc. (“IPS”), a leading provider of payment-enabled smart parking technology, from Windjammer Capital Investors in an all-cash transaction for a total consideration of $350 million.

Together, Nayax and IPS will offer cities, universities, and private operators a single differentiated platform that combines parking, payments, and EV charging at the curb. IPS contributes a market-leading vertical platform and an installed base of more than 250,000 parking spaces across the United States, Canada, the United Kingdom, and Ireland, a foundation Nayax will strengthen with its global payments infrastructure and extend internationally through its established commercial presence in over 120 countries. The acquisition immediately establishes Nayax as a leader in smart parking and expands its addressable cashless opportunity by approximately $85 billion, to approximately $342 billion by 2029.

“IPS gives Nayax a leading position at the curb, one of the most demanding and valuable environments in unattended commerce,” said Yair Nechmad, Chairman and Chief Executive Officer of Nayax. “Our ambition is to offer cities worldwide a comprehensive mobility solution with payments at its core, from parking to EV charging and beyond.”

“IPS has spent more than 20 years earning the trust of the cities and operators we serve,” said Chad Randall, Chief Executive Officer of IPS. “As part of Nayax, our customers gain a broader payments and EV charging ecosystem, and our platform gains a global stage.”

Transaction Details:

• Total enterprise value of $350 million in an all-cash transaction on a cash-free, debt-free basis, representing approximately 17x 2026E Adjusted EBITDA excluding anticipated synergies, and approximately 12x including run-rate synergies of more than $8 million.
• Nayax financed the transaction with cash on hand and approximately $150 million of new debt from Poalim Tech, the banking arm for tech companies of Bank Hapoalim, and First International Bank of Israel.
• Nayax reiterates that IPS is expected to have an FY 2026 revenue of more than $90 million, with more than 60% recurring revenue and approximately 20% organic growth over FY 2025, and Adjusted EBITDA of approximately $21 million with free cash flow conversion of approximately 80%.
• Nayax expects IPS to contribute approximately $20-22 million of revenue and greater than $5 million of Adjusted EBITDA to its FY 2026 results, reflecting the period from October 1, 2026 through December 31, 2026.
• The transaction is expected to be immediately accretive to gross margin, Adjusted EBITDA margin, Adjusted Earnings Per Share, and free cash flow conversion, and is aligned with Nayax’s progress toward its 2028 targets.
• Chad Randall and the IPS executive team will continue to lead the business from San Diego, California.

Advisors:

Jefferies LLC served as exclusive financial advisor and Reed Smith LLP served as legal counsel to Nayax. Poalim Tech, the banking arm for tech companies of Bank Hapoalim, and First International Bank of Israel provided debt financing to Nayax for the transaction. Harris Williams served as exclusive financial advisor and Kirkland & Ellis LLP served as legal counsel to IPS Group, Inc. and Windjammer Capital Investors.

About Nayax: 

Nayax is a global commerce enablement, payments, and loyalty platform designed to help merchants scale their business. Nayax offers a complete solution including localized cashless payment acceptance, management suite, and loyalty tools, enabling merchants to conduct commerce anywhere, at any time. With foundations and global leadership in serving unattended retail, Nayax has transformed into a comprehensive solution focused on our customers’ growth across multiple channels. As of June 30, 2026, Nayax has 13 global offices, approximately 1,250 employees, connections to more than 80 merchant acquirers and payment method integrations, and is globally recognized as a payment facilitator. Nayax’s mission is to improve our customers’ revenue potential and operational efficiency, effectively and simply. For more information, please visit www.nayax.com.

About IPS Group, Inc.:

Founded in 2000 and headquartered in San Diego, California, with offices in Canada and Europe, IPS Group, Inc. is an integrated payments, software, and data analytics platform powering smart parking and curb management for municipalities, universities, and private operators. IPS launched one of the first payment-enabled smart parking meters in 2005 and today delivers a fully integrated ecosystem spanning single and multi-space meters, mobile and text-based payments, and mission-critical parking management software. IPS manages more than 250,000 parking spaces across the United States, Canada, the United Kingdom, and Ireland.

Forward-Looking Statements:

This press release contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this press release can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “estimate” and “potential,” among others. Forward-looking statements include, but are not limited to, statements regarding our intent, belief or current expectations, such as statements in this press release regarding our financial outlook, future business prospects and the impact of recent acquisitions or partnerships published by the Company. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to: our expectations regarding general market conditions, including as a result of global economic trends; changes in consumer tastes and preferences; fluctuations in inflation, interest rate and exchange rates in the global economic environment; the availability of qualified personnel and the ability to retain such personnel; changes in commodity costs, labor, distribution and other operating costs; our ability to implement our growth strategy; changes in government regulation and tax matters; other factors that may affect our financial condition, liquidity and results of operations; general economic, political, demographic and business conditions in Israel; the success of operating initiatives, including advertising and promotional efforts and new product and concept development by us and our competitors; and other risk factors discussed under “Risk Factors” in our annual report on Form 20-F filed with the SEC on March 9, 2026 (our “Annual Report”). The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. The forward-looking statements are based on our beliefs, assumptions and expectations of future performance, taking into account the information currently available to us. These statements are only estimates based upon our current expectations and projections about future events. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements. In particular, you should consider the risks provided under “Risk Factors” in our Annual Report. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Each forward-looking statement speaks only as of the date of the particular statement. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason, to conform these statements to actual results or to changes in our expectations.

Public Relations Contact:
Scott Gamm
Strategy Voice Associates
Scott@strategyvoiceassociates.com

Investor Relations Contact:
Aaron Greenberg
Chief Strategy Officer
IR@nayax.com

Subsidiary-Level Investment Provides Capital to Advance Commercialization of the Company’s Antiviral Intellectual Property Portfolio with No Issuance of MGRX Common Stock

DALLAS, TEXAS, Oct. 01, 2026 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”), a company focused on developing, marketing, and selling health and wellness products through a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that its former wholly-owned subsidiary, MangoRx IP Holdings, LLC (“MangoRx IP”), has entered into subscription agreements with two strategic investors for an aggregate investment of $2.5 million directly into MangoRx IP, and has received the first tranche of $1.75 million due thereunder. Importantly, the investments are being made at the subsidiary level and do not involve the issuance of any shares of Mangoceuticals common stock, warrants or other securities of the publicly-traded parent company. Accordingly, the transactions do not increase the number of outstanding shares of Mangoceuticals or otherwise impact the Company’s public capitalization structure.

Under the terms of the agreements, the investors have committed to purchase an aggregate 25% membership interest in MangoRx IP for $2.5 million, payable in two tranches. The initial tranche consists of the equivalent of a 17.5% membership interest on a post-acquisition basis for $1.75 million, and the second tranche consists of the remaining 7.5% membership interest for $750,000, payable within 60 days following the initial closing, or by November 28, 2026, subject to the terms and conditions of the applicable subscription agreement.

We believe that the investment positions MangoRx IP to pursue opportunities across the full scope of its patent portfolio, which covers oral-surface administered preparations designed to help prevent illnesses acquired through the oral cavity and pharynx. In addition to poultry applications, we believe the technology has potential applications in livestock feed and water additives and in human oral-care formats, including toothpaste, mouthwash, lozenges, and oral sprays. According to Fortune Business Insights, the global oral care market was valued at approximately $34.8 billion in 2025, and the global feed additives market was valued at approximately $39.8 billion in 2025. The Company believes both markets are seeing growing demand for natural, non-antibiotic solutions, and that this breadth of application, supported by granted and pending patents across major markets, gives MangoRx IP multiple paths to potential monetization.

“We believe that this investment represents an important validation of the value we have built within MangoRx IP Holdings and provides us with additional capital to advance the next phase of commercialization, without issuing a single share of MGRX common stock,” said Jacob Cohen, Founder and Chief Executive Officer of Mangoceuticals. “We deliberately structured this investment at the subsidiary level to accomplish two key objectives: bring in strategic outside capital to help fund the commercialization of our intellectual property portfolio, while preserving the capital structure of Mangoceuticals and limiting dilution to our public shareholders. We also believe that having strategic investors aligned with MangoRx IP further strengthens our position as we pursue potential licensing, distribution and other commercialization opportunities.”

MangoRx IP owns the patent portfolio behind MGX-0024, the Company’s antiviral technology. The technology is protected in the U.S. under Patent No. 11,517,523, and corresponding national patents have been granted or are pending in the EU, Canada, China, India, Australia, and Japan.

The membership interests have been, and will be, offered and sold in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended, and/or Rule 506(b) of Regulation D. They have not been registered under the Securities Act or any state securities laws, and they may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities.

About Mangoceuticals, Inc.

MangoRx is focused on developing a variety of men’s health and wellness products and services via a secure telemedicine platform. The Company currently offers pharmaceutical-based products specifically related to the treatments of erectile dysfunction, hair growth, hormone replacement therapies, and weight management. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a licensed medical provider and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep. To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com.

Cautionary Note Regarding Forward-Looking Statements

Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995 (“forward-looking statements”). These forward-looking statements represent the Company’s current expectations or beliefs concerning future events and can generally be identified using statements that include words such as “estimate,” “expects,” “project,” “believe,” “anticipate,” “intend,” “plan,” “foresee,” “forecast,” “likely,” “will,” “target,” “up to” or similar words or phrases. These forward-looking statements include, but are not limited to, the timing and receipt of the second tranche of subscription funds discussed above, the use of the proceeds of the investments and the outcome thereof; the commercialization and monetization of MangoRx IP’s intellectual property; the review and evaluation of strategic transactions and their impact on shareholder value; the process by which the Company engages in evaluation of strategic transactions; the outcome of potential future strategic transactions and the terms thereof; macroeconomic, industry and market conditions, including inflation, interest rate volatility, recessionary trends, financial market disruptions, changes in regulatory or political environments, and other factors beyond the Company’s control that could adversely affect its business, financial condition and results of operations; our ability to meet the continued listing requirements of Nasdaq and maintain the listing of our common stock on Nasdaq, including as a result of our current non-compliance with certain listing standards relating to our stock price; our ability to successfully undertake a crypto treasury strategy in the future; risks related to the significant number of shares in the public float, our share volume, the effect of sales of a significant number of shares in the marketplace; dilution caused by offerings; conversion of outstanding shares of preferred stock and the rights and preferences thereof; the fact that we have a significant number of outstanding warrants to purchase shares of common stock and other convertible securities, the resale of which underlying shares have been registered under the Securities Act of 1933, as amended; dilution caused by exercises/conversions thereof, overhang related thereto, and decreases in the trading price of our common stock caused by sales thereof; our ability to build and maintain our brands; cybersecurity, information systems, fraud and website risks; compliance with applicable laws and regulations affecting our operations, products, marketing, manufacturing, labeling and distribution; shipping, production and supply chain delays; reliance on third parties for prescribing, compounding and other key services; product safety risks; geopolitical conditions, including pandemics, acts of war, tariffs and trade disruptions; protection of intellectual property; our ability to attract and retain key personnel; potential stock overhang and volatility in the trading price of our common stock; and consumer sentiment and discretionary spending trends. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements we make in this release are reasonable, we provide no assurance that these plans, intentions or expectations will be achieved. Consequently, you should not consider any such list to be a complete set of all potential risks and uncertainties.

More information on potential factors that could affect the Company’s financial results is included from time to time in the “Cautionary Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and subsequent reports. These filings are available at www.sec.gov and at our website at https://www.mangoceuticals.com/sec-filings. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements referenced above. Other unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

FOR INVESTOR RELATIONS
Mangoceuticals Investor Relations
Email: investors@mangorx.com

Frøya, 1 October 2026 – Kaldvik AS (“Kaldvik” or the “Company”) has entered into a waiver agreement with its lenders in relation to the Company’s financing facilities.

Reference is made to the Company’s stock exchange notices published on 6 and 15 September 2026 regarding the jellyfish event in Reyðarfjörður. The jellyfish event has negatively affected the Company’s biological production and financial position. As at 30 September 2026, the Company was not in compliance with the minimum liquidity covenant and the requirement to adjust the available amount under its revolving credit facility. The lenders have agreed to waive these requirements until and including 25 October 2026.

The waiver is subject to certain conditions, including ongoing reporting by the Company to the lenders regarding biological developments and the resulting financial position.

The Company and its lenders will continue the dialogue regarding a financial plan for the period following the expiry of the waiver.

For further information, please contact:
Vidar Aspehaug, CEO
+47 913 05 017

Þórunn Ragnarsdóttir, CFO
+354 822 7649

This information contains inside information and is disclosed pursuant to Article 17 of the EU Market Abuse Regulation (MAR), as incorporated into Icelandic law by Act No. 60/2021 on Measures Against Market Abuse, and section 5-12 of the Norwegian Securities Trading Act. The information was disclosed by Jón Kristinn Sverrisson, Compliance Officer, on the date and at the time indicated above.

About Kaldvík AS
Kaldvík is the leading salmon farmer in Iceland. Kaldvík has a well-developed and fully integrated value chain, enabling the Group to provide its customers with a sustainable premium product. Kaldvík is dual-listed on Euronext Growth Oslo and Nasdaq First North Growth Market Iceland. See www.kaldvik.is for more information about the Company.

The organization’s leadership, mission, ownership and commitment to community banking remain the same.

ELMIRA, N.Y., Oct. 01, 2026 (GLOBE NEWSWIRE) — Chemung Financial Corporation (NASDAQ: CHMG), parent company of Chemung Canal Trust Company, today announced its plans to unify Chemung Canal with its divisions, Capital Bank and Canal Bank, under a single name: Canal Bank & Trust, N.A.

Since 2011, the organization has served under multiple names across its footprint. Unifying as Canal Bank & Trust, N.A. will simplify customer experience, strengthen brand recognition and align the company’s branch network, digital channels, communications and long-term vision with one shared identity.

“This is a historic and important next step for our company,” said Anders M. Tomson, Chief Executive Officer of Chemung Canal Trust Company. “For nearly 200 years, our organization has grown while staying true to the principles that have defined us for generations: personal service, local decision-making, trusted relationships and a deep commitment to the communities we serve. The new Canal Bank & Trust, N.A. name honors that history while giving us a unified name that reflects where we came from, who we are today, and where we are heading.”

The company emphasized that the change is a brand unification only, and that there will be no change to its mission, leadership, ownership or community-banking approach. Customers will continue to work with the same local bankers and branch teams they know today, and the company will continue offering the same products, services and personal support.

The Canal Bank & Trust, N.A. name and logo will officially be introduced in the coming months and then be implemented across the company’s footprint throughout 2027. The rebranding process is expected to include branch and office signage, digital banking channels, company websites, social media platforms, marketing and communications and other customer touchpoints.

“This name change reflects our company’s roots and the region’s heritage,” said Jeffrey P. Kenefick, Regional President of Chemung Canal Trust Company. “The Bank was founded shortly after the opening of the Chemung Canal, the Bank’s namesake and an important waterway that helped connect communities and commerce. The Canal Bank & Trust, N.A. name will continue to represent connection, trust, financial progress and forward movement across our footprint,” Kenefick added.

No action is required by customers. Existing accounts, checks, debit cards, web and mobile banking, loan payments and other services will continue functioning as usual.

Chemung Financial Corporation is a $2.8 billion financial-services holding company headquartered in Elmira, New York, which operates 30 offices through its principal subsidiary, Chemung Canal Trust Company, a full-service community bank with full trust powers. Established in 1833, Chemung Canal Trust Company is the oldest locally owned and managed community bank in New York State. Chemung Financial Corporation is also the parent of CFS Group, Inc., a financial services subsidiary offering non-traditional services including mutual funds, annuities, brokerage services, tax preparation services and insurance.

Category: Financial

Source: Chemung Financial Corp

Contact:
Scott T. Heffner 
Senior Vice President
Director of Marketing
stheffner@chemungcanal.com

Collaboration advances Q/C Technologies’ optical processing unit initiative for AI inference through nanophotonics research at Sandia’s Center for Integrated Nanotechnologies

SAN FRANCISCO, Oct. 01, 2026 (GLOBE NEWSWIRE) — Q/C Technologies, Inc. (Nasdaq: QCLS) (“Q/C Technologies” or “the Company”), a developer of next-generation optical computing solutions, today announced a collaboration with the Center for Integrated Nanotechnologies (CINT) at Sandia National Laboratories (“Sandia”) to advance its proprietary optical processing unit (OPU) initiative for artificial intelligence inference. The Company is pioneering next-generation optical computing solutions designed to harness the properties of light to perform complex computations naturally via interference.

Sandia is one of the nation’s leading multi-mission science and engineering laboratories, operated for the U.S. Department of Energy’s National Nuclear Security Administration. With approximately 17,000 employees and an annual budget of approximately $5 billion, Sandia has deep capabilities spanning microelectronics, photonics, advanced materials, high-performance computing and systems engineering.

The Company’s collaboration with Sandia’s CINT focuses on joint research on nanophotonic components and the physical building blocks required for scalable optical AI processing. The project aims to establish and verify a defensible roadmap for optical AI hardware beyond incremental GPU scaling by identifying and prioritizing optical operations and device technologies for Q/C’s OPU architecture and addressing key challenges including nonlinear operations, memory, precision, optical loss and integration with electronic systems.

“Access to CINT’s scientific expertise and advanced research capabilities in photonics and nanoscale technologies represents an important step as we develop our proprietary optical computing platform,” said Joshua Silverman, Executive Chairman of Q/C Technologies. “As AI infrastructure faces increasing constraints in power consumption, bandwidth and scalability, we believe optical computing has the potential to fundamentally change how computationally intensive AI workloads are processed. This collaboration will help us evaluate key architectural concepts as we continue building the foundation for our next-generation optical computing solution.”

“This collaboration provides an opportunity to accelerate our work toward a practical, scalable optical computing architecture,” said Yossef Ehrlichman, Ph.D., Chief Technology Officer at Q/C Technologies. “We believe this work with CINT will help us define the pathway from fundamental optical capabilities to an integrated OPU architecture.”

The new collaboration represents another milestone in Q/C Technologies’ OPU initiative. The Company recently established a 4,800-square-foot integrated photonics laboratory in San Francisco and continues to build its foundation of knowledge and engineering expertise in AI, photonics and computing to support development of its proprietary OPU architecture.

About Q/C Technologies, Inc.

Q/C Technologies believes the next leap in frontier computing is optical. The Company is pioneering next-generation optical computing solutions designed to harness the properties of light to perform complex computations naturally via interference. Overcoming key challenges posed by electronic GPUs, Q/C Technologies seeks to develop proprietary optical processing units with orders of magnitude faster clock speed and bandwidth and vastly improved energy efficiency relative to traditional computing architectures. qctechnologies.com

Cautionary Statement Regarding Forward-Looking Statements

This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “may,” “plan,” “will,” “would’’ and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the development, performance and scalability of its optical computing products and related technologies, unanticipated financial setbacks, the Company needing to pursue financing options that could adversely impact its liabilities due to adverse market conditions, the Company’s ability to successfully develop new technologies; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company’s ability to patent and otherwise protect its technologies from competitors; the Company’s ability to retain and attract senior management, engineers and other key employees; and the Company’s ability to quickly and effectively respond to new technological developments. A discussion of these and other factors with respect to the Company is set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:
800-507-9010

Will invest to build championship-calibre teams
Will invest to deliver world-class experiences to fans and customers
Becomes global communications, sports and entertainment leader

TORONTO, Oct. 01, 2026 (GLOBE NEWSWIRE) — Rogers Communications Inc. announced today that it has completed the acquisition of Maple Leaf Sports & Entertainment (MLSE), increasing its ownership of MLSE to 100%. Rogers acquired the remaining 25% ownership stake in MLSE from Kilmer Sports Inc. for C$4.35 billion.

“We’re proud to bring these beloved teams together with the rest of Rogers to deliver more for fans, audiences, and customers,” said Tony Staffieri, President and CEO, Rogers. “We know how much these teams mean to fans and we are fully committed to investing to build championship-calibre teams, to enhancing the fan experience, and to delivering compelling experiences for our customers,” added Staffieri.

MLSE includes the Toronto Maple Leafs (NHL), Toronto Raptors (NBA), Toronto FC (MLS), Toronto Argonauts (CFL), the development teams affiliated with Toronto’s NHL and NBA franchises, Scotiabank Arena, and its partnership with Live Nation. Rogers current sports and entertainment portfolio includes the Toronto Blue Jays, Rogers Centre, Sportsnet, along with over 30 television networks and over 40 radio stations.

“MLSE has some of the most iconic sports teams, they are part of the fabric of our communities and our country,” said Edward Rogers, Executive Chair, Rogers. “Sports fans invest more than their money into their teams, they invest their time, passion and dreams. Their investment is personal and so is our responsibility.”

Rogers will create a new business unit, Rogers Sports, that brings Rogers sports, media and entertainment businesses together including MLSE and the Toronto Blue Jays.  Now that we have completed the acquisition, Rogers will now build the best operating model for Rogers Sports.

During the interim, it remains business as usual. Keith Pelley will remain President and CEO of MLSE and Mark Shapiro will remain President and CEO of the Toronto Blue Jays. Pelley will take on additional accountability for Rogers Media effective immediately.

“Individually, these are extraordinary teams, brands and businesses. With communications, sports and entertainment together, it makes Rogers a truly world-class company that cannot be replicated,” added Staffieri.

About Rogers Communications Inc.
Rogers is Canada’s communications, sports and entertainment company and its shares are publicly traded on the Toronto Stock Exchange (TSX: RCI.A and RCI.B) and on the New York Stock Exchange (NYSE: RCI). For more information, please visit rogers.com or about.rogers.com/investor-relations.

For further information:

Media Relations
media@rci.rogers.com
1-844-226-1338

Investor Relations
investor.relations@rci.rogers.com
1-844-801-4792